Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety
27.2.2023 23:33:00 EET | Business Wire | Press release
In a keynote address at the Fifth Global Ministerial Summit on Patient Safety, Joe Kiani, founder of the Patient Safety Movement Foundation (PSMF), called for hospitals around the world to show greater transparency in reporting medical errors and preventable deaths. He also stressed the importance of aligned incentives, so providers are paid on quality of care rather than quantity and the adoption of Actionable Evidence-Based Practices addressing the known causes of harm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005765/en/
Joe Kiani Provides Keynote at the 5th Annual Global Ministerial Summit on Patient Safety (Photo: Business Wire)
“We need not just access to healthcare, it has to be safe, it has to be dignified,” said Kiani. “To get there, we have to create self-governing actions. If we can agree on the medical errors that can be prevented through evidence-based practices, those then can be tracked by every hospital. And they could report every year, every quarter, on their website publicly, the number of harms they have for each of those errors.”
Transparency, Kiani argued, is critical because publicly revealing data on preventable medical errors helps to accelerate the pace of change.
In countries where healthcare is at least partially subsidized by the government, Kiani suggested introducing major financial incentives for hospitals to be more transparent and active in patient safety by implementing evidence-based practices for preventing errors.
“In my country, half of the care is paid for by the Government. Medicare and Medicaid pays for more than half the care in every hospital,” he said. “So therefore, they could mandate that to get that reimbursement, they want transparency, and that they will tie their performance to the payment. So if hospitals have zero medical errors, zero preventable deaths, they don't have to do anything. But if someone is harmed, and those evidence-based practices were not in place, they should not get paid. This becomes a way that every board of directors of every hospital will expect their management to implement evidence-based practices.”
As an example of how this can work, Kiani cited his time on the board of directors of Children's Hospital of Orange County (CHOC), California. “When I began at CHOC, I was happy to see they were looking at quality,” he said. “They were looking at medical errors, but they were comparing themselves to their colleagues, and if they were lower in error rate than others, that was considered a job well done. And I challenged them that shouldn't the goal be zero? To their credit, they accepted the challenge, and they went one step further, they tied the bonuses of the faculty to zero. Something incredible occurred at the next meeting, we went from hoping for zero, to planning for zero.”
“I want you all to take action out of kindness!” concluded Joe Kiani.
The Global Ministerial Summit on Patient Safety is an annual event that brings together ministers, high-level representatives, and experts from around the world. This year’s summit was hosted by President Alain Berset and the distinguished speakers included; Tedros Adhanom Ghebreyesus, Director-General, World Health Organization; Professor Didier Pittet, Professor of Medicine at the University of Geneva; Dr. Anthony Staines, Patient Safety Program Director of Vaud Hospital Federation in Switzerland; Professor Dr. Phil Lauren Clark, Professor of Implementation Science in Health Care; and Professor Sir Liam Donaldson, WHO Patient Safety Envoy.
This year the Patient Safety Movement Foundation will hold its 10th Annual World Patient Safety, Science & Technology Summit on June 1st and 2nd in Newport Beach, California.
ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION
In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP is available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005765/en/
Contact information
Patient Safety Movement Foundation
Irene Mulonni, irene@mulonni.com | (858) 859-7001
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
